Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.52 |
| ▸ | MMP9 | P14780 | 11/20 | 0.52 |
| ▸ | MMP13 | P45452 | 10/20 | 0.52 |
| ▸ | MMP8 | P22894 | 7/20 | 0.52 |
| ▸ | MMP3 | P08254 | 7/20 | 0.52 |
| ▸ | MMP1 | P03956 | 6/20 | 0.52 |
| ▸ | MMP7 | P09237 | 5/20 | 0.52 |
| ▸ | MMP14 | P50281 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083887 | 0.88 | MMP2 (0.51) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL3087707 | 0.81 | MMP2 (0.47) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL3090320 | 0.72 | ALDH1A1 (0.51) | LMNA | |
| SCHEMBL5198657 | 0.69 | LMNA (0.68) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL7761532 | 0.69 | MMP2 (1.00) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL7761520 | 0.69 | MMP2 (1.00) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL3090529 | 0.68 | MMP2 (0.59) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL6735964 | 0.65 | MMP2 (0.82) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL29259797 | 0.65 | CA1 (0.68) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL3078516 | 0.65 | MMP3 (0.45) | MMP2MMP9MMP13MMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | claimed |
| WO-2008024784-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | MMP3, MMP11, MMP13 | MMP2 14/4885MMP9 4/4885MMP13 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.